Oncopharmpod

Data Dive Into NK-1 Antagonists & Carboplatin

Informações:

Synopsis

ASCO's updated 2017 antiemetic guidelines recommend NK-1 antagonists to prevent CINV with standard Q 3 week carboplatin (i.e. AUC 5-6), but how good are the data to support that? We dive into the supporting data.